Literature DB >> 34143972

Immunotherapy in ovarian cancer: we are not there yet.

Emma Barber1, Daniela Matei2.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 34143972      PMCID: PMC9158516          DOI: 10.1016/S1470-2045(21)00303-X

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   54.433


× No keyword cloud information.
  9 in total

1.  Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Authors:  Leena Gandhi; Delvys Rodríguez-Abreu; Shirish Gadgeel; Emilio Esteban; Enriqueta Felip; Flávia De Angelis; Manuel Domine; Philip Clingan; Maximilian J Hochmair; Steven F Powell; Susanna Y-S Cheng; Helge G Bischoff; Nir Peled; Francesco Grossi; Ross R Jennens; Martin Reck; Rina Hui; Edward B Garon; Michael Boyer; Belén Rubio-Viqueira; Silvia Novello; Takayasu Kurata; Jhanelle E Gray; John Vida; Ziwen Wei; Jing Yang; Harry Raftopoulos; M Catherine Pietanza; Marina C Garassino
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

2.  Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.

Authors:  Mary L Disis; Matthew H Taylor; Karen Kelly; J Thaddeus Beck; Michael Gordon; Kathleen M Moore; Manish R Patel; Jorge Chaves; Haeseong Park; Alain C Mita; Erika P Hamilton; Christina M Annunziata; Hans Juergen Grote; Anja von Heydebreck; Jaspreet Grewal; Vikram Chand; James L Gulley
Journal:  JAMA Oncol       Date:  2019-03-01       Impact factor: 31.777

Review 3.  Single-cell genomic approaches for developing the next generation of immunotherapies.

Authors:  Ido Yofe; Rony Dahan; Ido Amit
Journal:  Nat Med       Date:  2020-02-03       Impact factor: 53.440

4.  Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.

Authors:  Catherine A Shu; Justin F Gainor; Mark M Awad; Codruta Chiuzan; Claud M Grigg; Aliyah Pabani; Robert F Garofano; Mark B Stoopler; Simon K Cheng; Abby White; Michael Lanuti; Frank D'Ovidio; Matthew Bacchetta; Joshua R Sonett; Anjali Saqi; Naiyer A Rizvi
Journal:  Lancet Oncol       Date:  2020-05-07       Impact factor: 41.316

5.  Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.

Authors:  Andrea Varga; Sarina Piha-Paul; Patrick A Ott; Janice M Mehnert; Dominique Berton-Rigaud; Anne Morosky; Ping Yang; Jane Ruman; Daniela Matei
Journal:  Gynecol Oncol       Date:  2018-12-03       Impact factor: 5.482

6.  Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.

Authors:  Eric Pujade-Lauraine; Keiichi Fujiwara; Jonathan A Ledermann; Amit M Oza; Rebecca Kristeleit; Isabelle-Laure Ray-Coquard; Gary E Richardson; Cristiana Sessa; Kan Yonemori; Susana Banerjee; Alexandra Leary; Anna V Tinker; Kyung Hae Jung; Radoslaw Madry; Sang-Yoon Park; Charles K Anderson; Fabian Zohren; Ross A Stewart; Caimiao Wei; Samuel S Dychter; Bradley J Monk
Journal:  Lancet Oncol       Date:  2021-06-15       Impact factor: 41.316

7.  Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.

Authors:  Panagiotis A Konstantinopoulos; Steven Waggoner; Gregory A Vidal; Monica Mita; John W Moroney; Robert Holloway; Linda Van Le; Jasgit C Sachdev; Eloise Chapman-Davis; Gerardo Colon-Otero; Richard T Penson; Ursula A Matulonis; Young Bae Kim; Kathleen N Moore; Elizabeth M Swisher; Anniina Färkkilä; Alan D'Andrea; Erica Stringer-Reasor; Jing Wang; Nathan Buerstatte; Sujata Arora; Julie R Graham; Dmitri Bobilev; Bruce J Dezube; Pamela Munster
Journal:  JAMA Oncol       Date:  2019-08-01       Impact factor: 31.777

8.  Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).

Authors:  Kathleen N Moore; Michael Bookman; Jalid Sehouli; Austin Miller; Charles Anderson; Giovanni Scambia; Tashanna Myers; Cagatay Taskiran; Katina Robison; Johanna Mäenpää; Lyndsay Willmott; Nicoletta Colombo; Jessica Thomes-Pepin; Michalis Liontos; Michael A Gold; Yolanda Garcia; Sudarshan K Sharma; Christopher J Darus; Carol Aghajanian; Aikou Okamoto; Xiaohua Wu; Rustem Safin; Fan Wu; Luciana Molinero; Vidya Maiya; Victor K Khor; Yvonne G Lin; Sandro Pignata
Journal:  J Clin Oncol       Date:  2021-04-23       Impact factor: 50.717

9.  High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy.

Authors:  Carsten Krieg; Malgorzata Nowicka; Silvia Guglietta; Sabrina Schindler; Felix J Hartmann; Lukas M Weber; Reinhard Dummer; Mark D Robinson; Mitchell P Levesque; Burkhard Becher
Journal:  Nat Med       Date:  2018-01-08       Impact factor: 87.241

  9 in total
  6 in total

Review 1.  Overview of Immune Checkpoint Inhibitors in Gynecological Cancer Treatment.

Authors:  Boštjan Pirš; Erik Škof; Vladimir Smrkolj; Špela Smrkolj
Journal:  Cancers (Basel)       Date:  2022-01-27       Impact factor: 6.639

2.  miR-600 promotes ovarian cancer cells stemness, proliferation and metastasis via targeting KLF9.

Authors:  Lili Shan; Pingping Song; Yangyang Zhao; Na An; Yanqiu Xia; Yue Qi; Hongyan Zhao; Jing Ge
Journal:  J Ovarian Res       Date:  2022-05-03       Impact factor: 5.506

3.  Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis.

Authors:  Duygu Ozmadenci; Jayanth S Shankara Narayanan; Jacob Andrew; Marjaana Ojalill; Allison M Barrie; Shulin Jiang; Samhita Iyer; Xiao Lei Chen; Michael Rose; Valeria Estrada; Alfredo Molinolo; Thomas Bertotto; Zbigniew Mikulski; Michael C McHale; Rebekah R White; Denise C Connolly; Jonathan A Pachter; Vijay K Kuchroo; Dwayne G Stupack; David D Schlaepfer
Journal:  Proc Natl Acad Sci U S A       Date:  2022-04-25       Impact factor: 12.779

4.  Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer.

Authors:  Siqi Chen; Ping Xie; Matthew Cowan; Hao Huang; Horacio Cardenas; Russell Keathley; Edward J Tanner; Gini F Fleming; John W Moroney; Alok Pant; Azza M Akasha; Ramana V Davuluri; Masha Kocherginsky; Bin Zhang; Daniela Matei
Journal:  J Clin Invest       Date:  2022-07-15       Impact factor: 19.456

Review 5.  The role of cancer-associated mesothelial cells in the progression and therapy of ovarian cancer.

Authors:  Aiping Zheng; Yuhao Wei; Yunuo Zhao; Tao Zhang; Xuelei Ma
Journal:  Front Immunol       Date:  2022-10-04       Impact factor: 8.786

Review 6.  Nanomedicine Strategies for Heating "Cold" Ovarian Cancer (OC): Next Evolution in Immunotherapy of OC.

Authors:  Yuqi Yang; Tianjiao Zhao; Qiaohui Chen; Yumei Li; Zuoxiu Xiao; Yuting Xiang; Boyu Wang; Yige Qiu; Shiqi Tu; Yitian Jiang; Yayun Nan; Qiong Huang; Kelong Ai
Journal:  Adv Sci (Weinh)       Date:  2022-07-22       Impact factor: 17.521

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.